Quality/TMF Administration Assistant – Join Our Team in Downey, CA!
CovarsaDx is seeking a dedicated and detail-oriented Quality/TMF Administration Assistant to play a pivotal role in managing Trial Master Files […]
How the Prevalence of COVID-19, Flu, and RSV is Shaping the Future of the IVD Industry
As respiratory illness season looms, bringing with it the usual suspects – COVID-19, influenza, and RSV – the demand for accurate and timely diagnostics has never been higher. With symptoms that blur the lines between these viruses, especially during peak seasons, healthcare providers are under pressure to deliver swift, precise diagnoses.
CovarsaDx’s Marielle Lejcher Shares Personal Health Journey on the ‘Speak Up for Your Health’ Podcast
CovarsaDx’s Vice President of Regulatory Affairs and Quality, Marielle Lejcher, recently shared her personal health journey on Dr. Archelle Georgiou’s Speak Up for Your Health podcast.
CovarsaDx Welcomes Rich Masino as Senior Director of Strategic Partnerships and Business Development
CovarsaDx, a clinical research organization at the forefront of in vitro diagnostics (IVD) and medical device trials, has appointed Rich Masino as senior director of strategic partnerships and business development. Bringing over 30 years of experience in biotech, pharma, and medical device diagnostics, Masino will focus on driving growth and forging strategic partnerships across CovarsaDx and ZoaDx, while reporting directly to the company’s chief executive officer (CEO).
Healgen’s At-Home COVID-19 and Influenza Test Achieves FDA De NovoStatus with Key Support from CovarsaDx® Research Team
CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its expertise in the areas of in vitro diagnostics (IVDs) and medical devices, proudly announced today that a clinical research study, conducted on behalf of Healgen Scientific, LLC, through the Independent Test Assessment Program (ITAP), part of National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech, has received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for the Healgen Rapid Check® COVID-19/Flu A&B Antigen Test.
CovarsaDx Expands Collaborative Efforts Through MDIC Membership and Key Initiatives
CovarsaDx is proud to announce its membership in the Medical Device Innovation Consortium (MDIC). This partnership marks a significant milestone in CovarsaDx’s ongoing mission to advance innovation in healthcare technology by providing reliable clinical validation results from an elite network of experienced investigators.